ArticleJAMA cardiology2017

Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial.

Alejandro Arrieta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.